Your browser is no longer supported. Please, upgrade your browser.
Indaptus Therapeutics, Inc.
Index- P/E- EPS (ttm)-16.41 Insider Own0.30% Shs Outstand5.80M Perf Week-12.50%
Market Cap51.16M Forward P/E- EPS next Y- Insider Trans- Shs Float2.88M Perf Month-10.91%
Income-19.00M PEG- EPS next Q- Inst Own4.40% Short Float1.89% Perf Quarter-38.24%
Sales- P/S- EPS this Y85.50% Inst Trans-12.06% Short Ratio0.01 Perf Half Y-47.75%
Book/sh- P/B- EPS next Y- ROA-92.00% Target Price- Perf Year-54.65%
Cash/sh- P/C- EPS next 5Y- ROE-131.10% 52W Range6.84 - 36.80 Perf YTD-36.09%
Dividend- P/FCF- EPS past 5Y26.00% ROI- 52W High-76.03% Beta1.13
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low28.95% ATR2.05
Employees70 Current Ratio3.50 Sales Q/Q- Oper. Margin- RSI (14)47.60 Volatility14.13% 20.24%
OptionableNo Debt/Eq0.00 EPS Q/Q-47.50% Profit Margin- Rel Volume0.27 Prev Close9.47
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume4.57M Price8.82
Recom- SMA20-3.42% SMA50-11.61% SMA200-41.57% Volume1,250,179 Change-6.86%
Sep-15-21 07:00AM  
Indaptus Therapeutics, Inc. engages in creating and advancing a pipeline of non-pathogenic gram-negative bacterial candidates to elicit broad and durable anti-tumor and anti-viral responses and cure disease. Its lead candidate is Decoy20 that is in pre-clinical studies to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma. The company is headquartered in New York, New York.